Sugi Predict

Sugi Predict / Compounds / SCHEMBL191467

SCHEMBL191467

SCHEMBL191467

COC(=O)NC(C(=O)O)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ LMNA P02545 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ PLA2G2A P14555 1/20 0.42
▸ PLA2G5 P39877 1/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.41
▸ TYR P14679 1/20 0.41
▸ FPR2 P25090 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CTSS P25774 1/20 0.39
▸ CTSK P43235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193562 1.00 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1LMNAGAAHPGD
SCHEMBL4994 1.00 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1LMNAGAAHPGD
Hydrochloric Acid SCHEMBL27589925 0.98 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1LMNAGAAHPGD
SCHEMBL28283143 0.92 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1LMNAGAAHPGD
SCHEMBL204822 0.92 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1LMNAGAAHPGD
SCHEMBL28462179 0.85 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1LMNAGAAHPGD
SCHEMBL28462181 0.85 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1LMNAGAAHPGD
SCHEMBL192729 0.84 CA2 (0.40) ALDH1A1CA2CA1CTSS
SCHEMBL3449046 0.84 CA2 (0.40) ALDH1A1CA2CA1CTSS
SCHEMBL16499390 0.84 CA2 (0.40) ALDH1A1CA2CA1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 955 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805306-A Production process of Yimitatawei 宜昌东阳光长江药业股份有限公司 2022-07-29 — — CN claimed
US-20200071337-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-03-05 — — US claimed
US-20190276468-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-09-12 — — US claimed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP claimed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US claimed
US-20180079744-A1 METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR SHANGHAI FOREFRONT PHARMACEUTICAL CO LTD (CN) 2018-03-22 — — US claimed
EP-3272747-A1 METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR Shanghai Forefront Pharmceutical Co., Ltd (CN) 2018-01-24 — — EP claimed
CN-107266428-A The synthesis of antiviral compound 吉利德制药有限责任公司 2017-10-20 — — CN claimed
CN-104520293-B Synthesis of Antiviral Compounds 吉利德制药有限责任公司 2017-07-28 — — CN claimed
EP-2855454-B1 SYNTHESIS OF ANTIVIRAL COMPOUND GILEAD PHARMASSET LLC (US) 2016-05-25 — — EP claimed
CN-104520293-A Synthesis of Antiviral Compounds GILEAD PHARMASSET LLC 2015-04-15 — — CN claimed
EP-2855454-A1 SYNTHESIS OF ANTIVIRAL COMPOUND Gilead Pharmasset LLC (US) 2015-04-08 — — EP claimed
WO-2013184702-A1 SYNTHESIS OF ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2013-12-12 — — WO claimed
US-20130324740-A1 SYNTHESIS OF ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2013-12-05 — — US claimed
US-8492371-B2 Compounds as cannabinoid receptor ligands ABBVIE INC. (US) 2013-07-23 — — US claimed
CN-102883718-A Analogues for the treatment or prevention of flavivirus infections VERTEX PHARMA 2013-01-16 — — CN claimed
EP-2515902-A1 ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2012-10-31 — — EP claimed
WO-2011079327-A1 ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-30 — — WO claimed
US-20100249129-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-30 — — US claimed
US-20090105306-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-04-23 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105306-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 SMN1; SMN2 3098/4885ALDH1A1 926/4885LMNA 2952/4885
US-20200071337-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 SMN1; SMN2 816/4885ALDH1A1 3925/4885LMNA 1463/4885
US-20100249129-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 SMN1; SMN2 3278/4885ALDH1A1 660/4885LMNA 3477/4885
US-20180079744-A1 METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR POLI, SAMHD1, TYMP SMN1; SMN2 3874/4885ALDH1A1 921/4885LMNA 1255/4885
US-20190276468-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 SMN1; SMN2 816/4885ALDH1A1 3925/4885LMNA 1463/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SMN1; SMN2 4141/4885ALDH1A1 2858/4885LMNA 3118/4885
US-20130324740-A1 SYNTHESIS OF ANTIVIRAL COMPOUND EIF2AK2, MAVS, SARS1 SMN1; SMN2 2594/4885ALDH1A1 2746/4885LMNA 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.